Physician profile
Michael Christopher
NPI 1477932796
$7,752.19
in general payments reported to CMS, 2019-2025
28 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,967 · 2020: $613 · 2021: $1,101 · 2022: $951 · 2023: $876 · 2024: $889 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.29 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,995.58 | 2019-2025 | |
| Abbvie INC. | $1,645.60 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $593.99 | 2019-2024 | Tremfya, Simponi, Remicade |
| Leo Pharma INC. | $450.56 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $445.99 | 2019-2024 | Taltz |
| Pfizer INC. | $352.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $308.11 | 2019-2025 | |
| Ucb, INC. | $269.86 | 2019-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $225.70 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $203.53 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $201.77 | 2019-2024 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $169.19 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.66 | 2021-2025 | Jublia |
| Amgen INC. | $133.86 | 2019-2025 | Otezla, Otezla |
| Allergan, INC. | $120.52 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $117.20 | 2019-2021 | |
| Epi Health, LLC | $74.86 | 2019-2021 | |
| Incyte Corporation | $63.79 | 2021-2025 | Opzelura |
| Krystal Biotech INC | $33.25 | 2024 | Vyjuvek |
| Dermira, INC. | $30.48 | 2019-2020 | |
| Journey Medical Corporation | $25.95 | 2024 | |
| Mayne Pharma Commercial LLC | $25.76 | 2023 | |
| Celgene Corporation | $24.33 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.04 | 2022 | |
| Prugen, INC. Pharmaceuticals | $21.83 | 2019 | |
| Dentsply Sirona INC | $18.46 | 2024 | Cavitron |
| E.R. Squibb & Sons, L.L.C. | $15.72 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.